The role of SATB2 in skeletogenesis and human disease

Cytokine and Growth Factor Reviews

Volumn 25, Issue 1, 2014, Pages 35-44

  Zhao, Xiaoying ^a   Qu, Zhihu ^b   Tickner, Jennifer ^c   Xu, Jiake ^c   Dai, Kerong ^a   Zhang, Xiaoling ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAITECH UNIVERSITY   (China)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Application in disease therapies; Expression; Function; SATB2; Skeletogenesis

Indexed keywords

AGENTS AFFECTING METABOLISM; BETA GALACTOSIDASE; BINDING PROTEIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE SIALOPROTEIN; CELL PROTEIN; CILIARY NEUROTROPHIC FACTOR; HISTONE DEACETYLASE 1; LEUKEMIA INHIBITORY FACTOR; MESSENGER RNA; METASTASIS ASSOCIATED PROTEIN 2; MICRORNA 31; MICRORNA 34; OSTEOCALCIN; OSTEOGENIC PROTEIN 1; PROTEIN HOXA2; RECEPTOR REGULATED SMAD PROTEIN; SMAD5 PROTEIN; SPECIAL AT RICH SEQUENCE BINDING PROTEIN 2; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

APRAXIA; AUTISM; BONE DEFECT; BONE DEVELOPMENT; BONE MINERALIZATION; BONE REGENERATION; BONE REMODELING; CANCER PROGNOSIS; CARCINOGENESIS; CARTILAGE CELL; CELL DIFFERENTIATION; CELL MATURATION; CELL MOTILITY; CELL NUCLEUS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; COLORECTAL CANCER; CORPUS CALLOSUM; CRANIOFACIAL MALFORMATION; CRANIOFACIAL SYNOSTOSIS; DIMERIZATION; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVITY; EPIGENETICS; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INSERTION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TARGETING; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC DISORDER; GENETIC SIMILARITY; HAPLOINSUFFICIENCY; HUMAN; IMMUNOREGULATION; LACZ GENE; MATRIX ATTACHMENT REGION; MICRODELETION SYNDROME; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PHENOTYPE; PLURIPOTENT STEM CELL; PONS; PRENATAL PERIOD; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RETROVIRUS; SATB2 GENE; SHORT SURVEY; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; TORIELLO CAREY SYNDROME; TRANSCRIPTION REGULATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

APPLICATION IN DISEASE-THERAPIES; EXPRESSION; FUNCTION; SATB2; SKELETOGENESIS;

ADULT; COLORECTAL NEOPLASMS; CRANIOSYNOSTOSES; CYTOKINES; EMBRYONIC DEVELOPMENT; FACIAL BONES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX ATTACHMENT REGION BINDING PROTEINS; OSTEOGENESIS; SKULL; TISSUE ENGINEERING; TRANSCRIPTION FACTORS;

EID: 84895811582     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2013.12.010     Document Type: Short Survey

References (61)

1. FitzPatrick D.R., Carr I.M., McLaren L., Leek J.P., Wightman P., Williamson K., et al. Identification of SATB2 as the cleft palate gene on 2q32-q33. Hum Mol Genet 2003, 12:2491-2501.
2. Dobreva G., Dambacher J., Grosschedl R. SUMO modification of a novel MAR-binding protein SATB2, modulates immunoglobulin μ gene expression. Genes Dev 2003, 17:3048-3061.
3. Dobreva G., Chahrour M., Dautzenberg M., Chirivella L., Kanzler B., Fariñas I., et al. SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. Cell 2006, 125:971-986.
4. Zhang J., Tu Q., Grosschedl R., Kim M.S., Griffin T., Drissi H., et al. Roles of SATB2 in osteogenic differentiation and bone regeneration. Tissue Eng Part A 2011, 17:1767-1776.
5. Glass I., Swindlehurst C., Aitken D., McCrea W., Boyd E. Interstitial deletion of the long arm of chromosome 2 with normal levels of isocitrate dehydrogenase. J Med Genet 1989, 26:127-130.
6. Yamaguchi A., Katagiri T., Ikeda T., Wozney J.M., Rosen V., Wang E.A., et al. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol 1991, 113:681-687.
7. Katagiri T., Yamaguchi A., Komaki M., Abe E., Takahashi N., Ikeda T., et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 1994, 127:1755-1766.
8. Ryoo H.-M., Lee M.-H., Kim Y.-J. Critical molecular switches involved in BMP-2-induced osteogenic differentiation of mesenchymal cells. Gene 2006, 366:51-57.
9. Lee K.-S., Kim H.-J., Li Q.-L., Chi X.-Z., Ueta C., Komori T., et al. Runx2 is a common target of transforming growth factor β1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000, 20:8783-8792.
10. Lee M.H., Javed A., Kim H.J., Shin H.I., Gutierrez S., Choi J.Y., et al. Transient upregulation of CBFA1 in response to bone morphogenetic protein-2 and transforming growth factor beta1 in C2C12 myogenic cells coincides with suppression of the myogenic phenotype but is not sufficient for osteoblast differentiation. J Cell Biochem 1999, 73:114-125.
11. Lee M.H., Kim Y.J., Kim H.J., Park H.D., Kang A.R., Kyung H.M., et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 2003, 278:34387-34394.
12. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
13. Lee M.-H., Kwon T.-G., Park H.-S., Wozney J.M., Ryoo H.-M. BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2. Biochem Biophys Res Commun 2003, 309:689-694.
14. Bonilla-Claudio M., Wang J., Bai Y., Klysik E., Selever J., Martin J.F. Bmp signaling regulates a dose-dependent transcriptional program to control facial skeletal development. Development 2012, 139:709-719.
15. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
16. Hassan M.Q., Gordon J.A., Beloti M.M., Croce C.M., Van Wijnen A.J., Stein J.L., et al. A network connecting Runx2 SATB2, and the miR-23a~27a~24-2 cluster regulates the osteoblast differentiation program. Proc Natl Acad Sci USA 2010, 107:19879-19884.
17. Aprelikova O., Yu X., Palla J., Wei B.-R., John S., Yi M., et al. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle 2010, 9:4387-4398.
18. Deng Y., Wu S., Zhou H., Bi X., Wang Y., Zhao P., et al. Effects of a miR-31 Runx2 and Satb2 regulatory loop on the osteogenic differentiation of bone marrow mesenchymal stem cells. Stem Cells Dev 2013, 22:2278-2286.
19. Tang W., Li Y., Osimiri L., Zhang C. Osteoblast-specific transcription factor Osterix (Osx) is an upstream regulator of Satb2 during bone formation. J Biol Chem 2011, 286:32995-33002.
20. Wei J., Shi Y., Zheng L., Zhou B., Inose H., Wang J., et al. miR-34s inhibit osteoblast proliferation and differentiation in the mouse by targeting SATB2. J Cell Biol 2012, 197:509-521.
21. Freude T., Braun K.F., Haug A., Pscherer S., Stöckle U., Nussler A.K., et al. Hyperinsulinemia reduces osteoblast activity in vitro via upregulation of TGF-β. J Mol Med 2012, 90:66-1257.
22. Mao X.Y., Tang S.J. Effects of phenytoin on Satb2 and Hoxa2 gene expressions in mouse embryonic craniofacial tissue. Biochem Cell Biol 2010, 88:731-735.
23. Apostolova G., Loy B., Dorn R., Dechant G. The sympathetic neurotransmitter switch depends on the nuclear matrix protein Satb2. J Neurosci 2010, 30:64-16356.
24. Gyorgy A.B., Szemes M., De Juan Romero C., Tarabykin V., Agoston D.V. SATB2 interacts with chromatin-remodeling molecules in differentiating cortical neurons. Eur J Neurosci 2008, 27:73-865.
25. Forrester W.C., van Genderen C., Jenuwein T., Grosschedl R. Dependence of enhancer-mediated transcription of the immunoglobulin mu gene on nuclear matrix attachment regions. Science 1994, 265:5-1221.
26. Ellies D.L., Krumlauf R. Bone formation: the nuclear matrix reloaded. Cell 2006, 125:840-842.
27. Kim I.-S., Jeong S.-J., Kim S.-H., Jung J.H., Park Y.G., Kim S.-H. Special AT-rich sequence-binding protein 2 and its related genes play key roles in the differentiation of MC3T3-E1 osteoblast like cells. Biochem Biophys Res Commun 2012, 417:697-703.
28. Zhang P., Men J., Fu Y., Shan T., Ye J., Wu Y., et al. Contribution of SATB2 to the stronger osteogenic potential of bone marrow stromal cells from craniofacial bones. Cell Tissue Res 2012, 350:425-437.
29. Wei J.D., Lin Y.L., Tsai C.H., Shieh H.S., Lin P.I., Ho W.P., et al. SATB2 participates in regulation of menadione-induced apoptotic insults to osteoblasts. J Orthop Res 2012, 30:66-1058.
30. Britanova O., Depew M.J., Schwark M., Thomas B.L., Miletich I., Sharpe P., et al. Satb2 haploinsufficiency phenocopies 2q32-q33 deletions, whereas loss suggests a fundamental role in the coordination of jaw development. Am J Hum Genet 2006, 79:668-678.
31. Brewer C.M., Leek J.P., Green A.J., Holloway S., Bonthron D.T., Markham A.F., et al. A locus for isolated cleft palate, located on human chromosome 2q32. Am J Hum Genet 1999, 65:387.
32. Leoyklang P., Suphapeetiporn K., Siriwan P., Desudchit T., Chaowanapanja P., Gahl W.A., et al. Heterozygous nonsense mutation SATB2 associated with cleft palate, osteoporosis, and cognitive defects. Hum Mutat 2007, 28:732-738.
33. Van Buggenhout G., Van Ravenswaaij-Arts C., Mc Maas N., Thoelen R., Vogels A., Smeets D., et al. The del (2)(q32.2q33) deletion syndrome defined by clinical and molecular characterization of four patients. Eur J Med Genet 2005, 48:276-289.
34. Benson K., Gordon M., Wassman E.R., Tsi C., Opitz J.M., Reynolds J.F. Interstitial deletion of the long arm of chromosome 2 in a malformed infant with karyotype 46 XX, del (2)(q31q33). Am J Med Genet 1986, 25:405-411.
35. Urquhart J., Black G.C., Clayton-Smith J. 4.5Mb microdeletion in chromosome band 2q33.1 associated with learning disability and cleft palate. Eur J Med Genet 2009, 52:454-457.
36. Tegay D., Chan K., Leung L., Wang C., Burkett S., Stone G., et al. Toriello-Carey syndrome in a patient with a de novo balanced translocation [46 XY, t (2; 14)(q33; q22)] interrupting SATB2. Clin Genet 2009, 75:259-264.
37. de Carvalho Maretti M.B., Haddad A.S., Ferreira M.C.D., de Oliveira Guaré R., Alonso L.G. Toriello Carey syndrome: genetic, clinical, and oral considerations: a case report. Spec Care Dentist 2011, 31:68-72.
38. Said E., Cuschieri A., Vermeesch J., Fryns J.P. Toriello-Carey syndrome with a 6Mb interstitial deletion at 22q12 detected by array CGH. Am J Med Genet A 2011, 155:1390-1392.
39. El-Chammas K.I., Venkatasubramani N., Veith R., Sekhri N., Rhead W., Toriello H.V., et al. Pancreatic insufficiency in Toriello-Carey syndrome: report of a second patient. Am J Med Genet A 2012, 158:11-1208.
40. Wegner K.J., Hersh J.A. Toriello-Carey syndrome: an additional case and summary of previously reported cases. Clin Dysmorphol 2001, 10:145-148.
41. Toriello H.V., Carey J.C., Addor M.C., Allen W., Burke L., Chun N., et al. Toriello-Carey syndrome: delineation and review. Am J Med Genet A 2003, 123:84-90.
42. Marshall C.R., Noor A., Vincent J.B., Lionel A.C., Feuk L., Skaug J., et al. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 2008, 82:477-488.
43. Houdayer C., Portnoï M.F., Vialard F., Soupre V., Crumière C., Taillemite J.L., et al. Pierre Robin sequence and interstitial deletion 2q32.3-q33.2. Am J Med Genet 2001, 102:219-226.
44. Balasubramanian M., Smith K., Basel-Vanagaite L., Feingold M., Brock P., Gowans G., et al. Case series: 2q33.1 microdeletion syndrome-further delineation of the phenotype. J Med Genet 2011, 48:290-298.
45. Rosenfeld J.A., Ballif B.C., Lucas A., Spence E.J., Powell C., Aylsworth A.S., et al. Small deletions of SATB2 cause some of the clinical features of the 2q33.1 microdeletion syndrome. PLoS ONE 2009, 4:6568.
46. de Ravel T.J., Balikova I., Thiry P., Vermeesch J.R., Frijns J.-P. Another patient with a de novo deletion further delineates the 2q33.1 microdeletion syndrome. Eur J Med Genet 2009, 52:120-122.
47. Coussens A.K., Hughes I.P., Wilkinson C.R., Morris C.P., Anderson P.J., Powell B.C., et al. Identification of genes differentially expressed by prematurely fused human sutures using a novel in vivo-in vitro approach. Differentiation 2008, 76:531-545.
48. Ye J.-H., Xu Y.-J., Gao J., Yan S.-G., Zhao J., Tu Q., et al. Critical-size calvarial bone defects healing in a mouse model with silk scaffolds and SATB2-modified iPSCs. Biomaterials 2011, 32:76-5065.
49. Yan S., Zhang J., Tu Q., Ye J., Luo E., Schuler M., et al. Enhanced osseointegration of titanium implant through the local delivery of transcription factor SATB2. Biomaterials 2011, 32:83-8676.
50. Tu Q., Zhang J., James L., Dickson J., Tang J., Yang P., et al. Cbfa1/Runx2-deficiency delays bone wound healing and locally delivered Cbfa1/Runx2 promotes bone repair in animal models. Wound Repair Regen 2007, 15:404-412.
51. Tu Q., Valverde P., Li S., Zhang J., Yang P., Chen J. Osterix overexpression in mesenchymal stem cells stimulates healing of critical-sized defects in murine calvarial bone. Tissue Eng 2007, 13:40-2431.
52. Tu Q., Valverde P., Chen J. Osterix enhances proliferation and osteogenic potential of bone marrow stromal cells. Biochem Biophys Res Commun 2006, 341:65-1257.
53. Ramer J.C., Mowrey P.N., Robins D.B., Ligato S., Towfighi J., Ladda R.L. Five children with del (2)(q31q33) and one individual with dup (2)(q31q33) from a single family: review of brain, cardiac, and limb malformations. Am J Med Genet 1990, 37:392-400.
54. Ramer J.C., Ladda R.L., Frankel C.A., Beckford A. A review of phenotype-karyotype correlations in individuals with interstitial deletions of the long arm of chromosome 2. Am J Med Genet 1989, 32:359-363.
55. Al-Awadi S., Farag T., Naguib K., Teebi A., Cuschieri A., Al-Othman S., et al. Interstitial deletion of the long arm of chromosome 2: del (2)(q31q33). J Med Genet 1983, 20:464-465.
56. Taysi K., Dengler D., Jones L., Heersma J. Interstitial deletion of the long arm of chromosome 2: case report and review of literature. Ann Genet 1981, p245.
57. Vogels A., Haegeman J., Fryns J.-P. Pierre-Robin sequence and severe mental retardation with chaotic behaviour associated with a small interstitial deletion in the long arm of chromosome 2 (del (2)(q331q333)). Genet Couns 1997, 8:249-252.
58. Young R.S., Shapiro S., Hansen K.L., Hine L., Rainosek D., Guerra F. Deletion 2q: two new cases with karyotypes 46, XY, del (2)(q31q33) and 46, XX, del (2)(q36). J Med Genet 1983, 20:199-202.
59. Hiroyama Y., Hatanaka H., Ikenoue T., Ishihara Y. Interstitial deletion of long arm of chromosome 2(q31q33). Acta Paediatr Jpn 1990, 32:563-565.
60. Buchanan P.D., Rhodes R.L., Stevenson C.E. Interstitial deletion 2q31 leads to q33. Am J Med Genet 1983, 15:121-126.
61. Franceschini P., Silengo M.C., Davi G., Bianco R., Biagioli M. Interstitial deletion of the long arm of chromosome 2 (q31q33) in a girl with multiple anomalies and mental retardation. Hum Genet 1983, 64:98.